{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:04:04Z","timestamp":1788386644446,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Our goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) since the 2016 MASCC\/ESMO antiemetic update and classify their emetic potential.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The MASCC\/ESMO Expert Panel classified the emetogenicity of the identified new antineoplastic agents based on nonsystematic reviews of randomized controlled trials, analysis of product labeling, and evaluation of emetic classification in other international guidelines and informal consensus. The emetogenic classification system for oral anticancer agents was revised into two emetic risk categories (minimal\u2013low; moderate\u2013high) to be consistent with the system reported by ASCO (American Society of Clinical Oncology) in their 2017 guideline update. The previously employed four emetic risk classification categories for intravenously administered antineoplastic agents were retained for this update.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From June 2015 to January 2023, 107 new antineoplastic agents (44 intravenously administered and 63 orally administered agents) were identified. The reported incidence of vomiting varied significantly across studies for many agents, especially for oral anticancer agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The MASCC\/ESMO Expert Panel acknowledges the limitations of our efforts to classify the emetic potential of anticancer agents, especially the imprecision associated with oral agents. However, we have attempted to provide a reasonable approximation of the emetic risk associated with new antineoplastic agents by searching the available literature and reviewing other available international antiemetic guidelines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-08220-5","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:02:15Z","timestamp":1703206935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents\u2014updated MASCC\/ESMO consensus recommendation"],"prefix":"10.1007","volume":"32","author":[{"given":"Karin","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"8220_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865\u2013869","journal-title":"N Engl J Med"},{"key":"8220_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00520-004-0718-y","volume":"13","author":"SM Grunberg","year":"2005","unstructured":"Grunberg SM, Osoba D, Hesket h PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013an update. Support Care Cancer 13:80\u201384","journal-title":"Support Care Cancer"},{"key":"8220_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19 Suppl 1","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013state of the art. Support Care Cancer 19 Suppl 1:S43-47","journal-title":"Support Care Cancer"},{"key":"8220_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s005200050157","volume":"6","author":"PJ Hesketh","year":"1998","unstructured":"Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221\u2013227","journal-title":"Support Care Cancer"},{"key":"8220_CR5","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797","journal-title":"J Clin Oncol"},{"key":"8220_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103\u2013109","journal-title":"J Clin Oncol"},{"key":"8220_CR7","doi-asserted-by":"crossref","unstructured":"Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ (2016) Updated MASCC\/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 2017(25):271\u2013275","DOI":"10.1007\/s00520-016-3332-x"},{"key":"8220_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081\u20131090","journal-title":"Ann Oncol"},{"key":"8220_CR9","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MG Kris","year":"2006","unstructured":"Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932\u20132947","journal-title":"J Clin Oncol"},{"key":"8220_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mdj078","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Hesketh PJ, Herrstedt J (2006) Antiemetic subcommitte of the multinational association of supportive care in cancer: prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 perugia international antiemetic consensus conference. Ann Oncol 17:20\u201328","journal-title":"Ann Oncol"},{"issue":"27","key":"8220_CR11","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"2016","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M (2016) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016(27):v119\u2013v133","journal-title":"Ann Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08220-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08220-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T05:03:04Z","timestamp":1705381384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08220-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["8220"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08220-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"1 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have the following conflicts of interest to disclose:Karin Jordan: reports personal fees as an invited speaker from Amgen, art tempi, Helsinn, Hexal, med update GmbH, MSD, Mundipharma, onkowissen, Riemser, Roche, Shire (Takeda), and Vifor; personal fees for advisory board membership from Amgen, AstraZeneca, BD Solutions, Hexal, Karyopharm, and Voluntis; personal fees as author for UpToDate.Alexandre Chan: received honorarium from Eli Lilly, Blueprint Medicine, and HengRui USA.Richard J. Gralla: received honoraria from Fosun, Helsinn Healthcare SA, Juniper Biologics, Knight Therapeutics, Mundipharma International Limited, Vifor Pharma.Franziska Jahn: received honorarium and a travel grant from Amgen.Bernardo Rapoport: reports personal fees as an invited speaker from MSD, personal fees, and a research grant from Tesaro (GSK now).Christina Ruhlmann: received honoraria (speaker) from Bristol Myers Squibb (BMS), Helsinn Healthcare SA, and Pharmanovia, and funding for a clinical trial from Helsinn Healthcare SA and the Novo Nordic Foundation.Paula Sayegh: nothing to disclose.Paul J. Hesketh: nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"53"}}